We foresee that human monoclonal IgE as they become more readily available will continue to prove their extensive value in defining allergy-causing immune responses and in providing new solutions (e.g. new hypoallergenic variants as described in the past 18) that may be used to treat allergic disease in the clinic. Here, IGHE is linked to allergic disease.